Discovery of RAF265: A Potent mut-B-RAF inhibitor for the treatment of metastatic melanoma

ACS Medicinal Chemistry Letters

Volumn 6, Issue 9, 2015, Pages 961-965

  Williams, Teresa E ^a   Subramanian, Sharadha ^a   Verhagen, Joelle ^a   McBride, Christopher M ^a   Costales, Abran ^a   Sung, Leonard ^a   Antonios Mccrea, William ^a   McKenna, Maureen ^a   Louie, Alicia K ^a   Ramurthy, Savithri ^a   Levine, Barry ^a   Shafer, Cynthia M ^a   MacHajewski, Timothy ^a   Renhowe, Paul A ^a   Appleton, Brent A ^a   Amiri, Payman ^a   Chou, James ^a   Stuart, Darrin ^a   Aardalen, Kimberly ^a   Poon, Daniel ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

b raf; map; serine threonine kinases; tyrosine kinases; vegf

Indexed keywords

B RAF KINASE; CHIR 265; MITOGEN ACTIVATED PROTEIN KINASE;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION ASSAY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SYNTHESIS; ENZYMATIC ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROGEN BOND; IC50; IN VITRO STUDY; IN VIVO STUDY; METASTATIC MELANOMA; NONHUMAN; PLASMA CLEARANCE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR REGRESSION; WESTERN BLOTTING;

EID: 84941567872     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500526p     Document Type: Article

References (22)

1. Santarpia, L.; Lippman, S. M.; El- Naggar, A. K. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy Expert Opin. Ther. Targets 2012, 16, 103-119 10.1517/14728222.2011.645805
2. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Shall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W. C.; Leueng, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the B-RAF gene in human cancer Nature 2002, 417, 949-954 10.1038/nature00766
3. Martin-Liberal, J.; Larkin, J. New RAF kinase inhibitors in cancer therapy Expert Opin. Pharmacother. 2014, 15, 1235-1245 10.1517/14656566.2014.911286
4. Bollag, G.; Tsai, J.; Zhang, J.; Zhang, C.; Ibrahim, P.; Nolop, K.; Hirth, P. Vemurafenib: the first drug approved for BRAF-mutant cancer Nat. Rev. Drug Discovery 2012, 11, 873-886 10.1038/nrd3847
5. Rheault, T. R.; Stellwagen, J. C.; Adjabeng, G. M.; Hornberger, K. R.; Petrov, K. G.; Waterson, A. G.; Dickerson, S. H.; Mook, R. A.; Laquerre, S. G.; King, A. J.; Rossanese, O. W.; Arnone, M. R.; Smitheman, K. N.; Kane-Carson, L. S.; Han, C.; Moorthy, G. S.; Moss, K. G.; Uehling, D. E. Discovery of Dabrafenib: A selective inhibitor of Raf kinases with antitumor activity against B-Raf driven tumors ACS Med. Chem. Lett. 2013, 4, 358-362 10.1021/ml4000063
6. Ramurthy, S.; Subramanian, S.; Aikawa, M.; Amiri, P.; Costales, A.; Dove, J.; Fong, S.; Jansen, J. M.; Levine, B.; Ma, S.; McBride, C. M.; Michaelian, J.; Pick, T.; Poon, D. J.; Girish, S.; Shafer, C. M.; Stuart, D.; Sung, L.; Renhowe, P. A. Design and Synthesis of Orally Bioavailable Benzimidazoles as RAF kinasse inhibitors J. Med. Chem. 2008, 51, 7049-7052 10.1021/jm801050k
7. Subramanian, S.; Costales, A.; Williams, T.; Levine, B.; McBride, C.; Poon, D.; Amiri, P.; Renhowe, P.; Shafer, C.; Stuart, D.; Verhagen, J.; Ramurthy, S. Design and synthesis of orally bioavailable benzimidazole reverse amides as pan-RAF kinase inhibitors ACS Med. Chem. Lett. 2014, 5, 989-992 10.1021/ml5002272
8. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R. A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat. Rev. Drug Discovery 2006, 5, 835-844 10.1038/nrd2130
9. Tsai, J.; Lee, J. T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N. K.; Sproesser, K.; Li, L.; Smalley, K. S. M.; Fong, D.; Zhu, Y. L.; Marimuthu, A.; Nguyen, H.; Lam, B.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S. H.; Schlessinger, J.; Zhange, K. Y. J.; West, B. L.; Powell, B.; Habets, G.; Zhang, C.; Ibrahim, P. N.; Hirth, P.; Artis, D. R.; Herlyn, M.; Bollag, G. Discovery of a selective inhibitor or oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 3041-3046 10.1073/pnas.0711741105
10. Brown, S. A.; Rizzo, C. J. A "one-pot"phase transfer alkylation/hydrolysis of o-nitrotrifluoroacetanilides. A convenient route to N-alkyl 0-phenylenediamines Synth. Commun. 1996, 26, 4065-4080 10.1080/00397919608003827
11. McKillop, A.; Fiaud, J. C.; Hug, R. P. The use of phase- transfer catalysis for the synthesis of phenol ethers Tetrahedron 1974, 30, 1379-1382 10.1016/S0040-4020(01)97250-3
12. Baldwin, J. J.; Kasinger, P. A.; Novello, F. C.; Sprague, J. M. 4-Trifluoromethylimidazoles and 5-(4-pyridyl)-1,2,4-triazoles, new classes of xanthine oxidase inhibitors J. Med. Chem. 1975, 18, 895-900 10.1021/jm00243a007
13. An alternative process procedure has been described: Artman, G.; Solovay, C. F.; Adams, C. M.; Diaz, B.; Dimitroff, M.; Ehara, T.; Gu, D.; Ma, F.; Liu, D.; Miller, B. R.; Pick, T. E.; Poon, D. J.; Ryckman, D.; Siesel, D. A.; Stillwell, B. S.; Swiftney, T.; van Dyck, J. P.; Zhang, C.; Ji, N. One pot synthesis of aminobenzimidazoles using 2-chloro-1,2-dimethylimidazolium chloride (DMC) Tetrahedron Lett. 2010, 51, 5319-5321 10.1016/j.tetlet.2010.07.177
14. Tyagarajan, S.; Chakravarty, P. K.; Zhou, B.; Fisher, M. H.; Wyvratt, M. J.; Lyons, K.; Klatt, T.; Li, X.; Kumar, S.; Williams, B.; Felix, J.; Priest, B. T.; Brochu, R. M.; Warren, V.; Smith, M.; Garcia, M.; Kaczorowski, G. J.; Martin, W. J.; Abbadie, C.; McGowan, E.; Jochnowitz, N.; Parsons, W. H. Substitutied biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers Bioorg. Med. Chem. Lett. 2010, 20, 5536-5540 10.1016/j.bmcl.2010.07.064
15. Coordinates and structure factors have been deposited in the Protein Data Bank (www.rcsb.org) with the accession code 5ct7.
16. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 2009, 9, 28-39 10.1038/nrc2559
17. Smith, A. L.; DeMorin, F. F.; Paras, N. A.; Huang, Q.; Petkus, J. K.; Doherty, E. M.; Nixey, T.; Kim, J. L.; Whittington, D. A.; Epstein, L. F.; Lee, M. R.; Rose, M. J.; Babij, C.; Fernando, M.; Hess, K.; Le, Q.; Beltran, P.; Carnahan, J. Selective inhibitors of the mutant-B-RAF Pathway: Discovery of a Potent and Orally Bioavailable Aminoisoquinoline J. Med. Chem. 2009, 52, 6189-6192 10.1021/jm901081g
18. Kumar, R.; Crouthamel, M. C.; Rominger, D. H.; Gontarek, R. R.; Tummino, P. J.; Levin, R. A.; King, A. G. Myelosupression and kinase selectivity of multikinase angiogenesis inhibitors Br. J. Cancer 2009, 101, 1717-1723 10.1038/sj.bjc.6605366
19. A broad kinase survey was conducted on RAF265 and other kinase inhibitors: Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-132 10.1038/nbt1358
20. Melnick, J. S.; Janes, J.; Kim, S.; Chang, J. Y.; Sipes, D. G.; Gunderson, D.; Jarnes, L.; Matzen, J. T.; Garcia, M. E.; Hood, T. L.; Beigi, R.; Cia, G.; Harig, R. A.; Asatryan, H.; Yan, S. F.; Zhou, Y.; Gu, X. J.; Saadat, A.; Zhou, V.; King, F. J.; Shaw, C. M.; Su, A. I.; Downs, R.; Gray, N. S.; Schultz, P. G.; Warmuth, M.; Caldwell, J. S. An efficient rapid system for profiling the cellular activities of molecular libraries Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 3153-3158 10.1073/pnas.0511292103
21. Arnott, J. A.; Planey, S. L. The influence of lipophilicity in drug discovery and design Expert Opin. Drug Discovery 2012, 7, 863-875 10.1517/17460441.2012.714363
22. Novartis Pharmaceuticals. A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma. http://clinicaltrials.gov/show/NCT00304525 (NLM Identifier: NCT00304525).